Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Loewenstein, Anat http://orcid.org/0000-0002-7706-1165
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Bandello, Francesco http://orcid.org/0000-0003-3238-9682
Kuppermann, Baruch D.
Article History
Received: 16 October 2023
Revised: 17 October 2023
Accepted: 24 October 2023
First Online: 4 November 2023
Competing interests
: AS—consultant: Novartis, Allergan, Bayer, Lupin and Intas and speaker fee: Biogen. AL—consultant: Allergan, Novartis, Roche, Notal Vision, ForSight Labs, Beyeonics, Bayer Health Care. NP—None. NK—None. FB—consultant: Allergan, Bayer, Boehringer Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK—clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics and consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma.